US DoD Naval Medical Research Center Reports Positive Immunological Responses to VaccineGlobeNewsWire • 11/11/20
Immuron Limited Announces Closing of $20.0 Million Registered Direct OfferingGlobeNewsWire • 07/23/20
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeuticGlobeNewsWire • 07/20/20
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of DefenseGlobeNewsWire • 06/19/20
Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDAMarket Watch • 06/09/20
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious DiarrheaGlobeNewsWire • 06/09/20
Immuron’s Technology Platform of Treatments in the Age of the Coronavirus OutbreakGlobeNewsWire • 02/03/20